Business Model Breakdown
How Armata Pharmaceuticals Inc Makes Money
ARMP
Market Cap
$473M
Annual Revenue
$1M
Profit Margin
-3544.0%
Employees
60
The Short Version
Armata Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing novel bacteriophage-based therapeutics. These therapies are designed to precisely target and kill specific bacteria, offering a potential solution to serious bacterial infections, especially those resistant to conventional antibiotics. The company's business model is currently focused on research and development, raising capital to fund its clinical trials. If successful, Armata aims to generate revenue by bringing its approved phage therapies to market, potentially through licensing agreements with larger pharmaceutical companies or direct commercialization, selling its products to hospitals and healthcare providers.
Where the Revenue Comes From
Currently negligible, primarily from grants or collaborations (~0-1% of future revenue)
Future product sales of approved phage therapeutics (~95-100% of future revenue)
Who buys: Hospitals, healthcare systems, potentially government entities (for biodefense or stockpiling for public health crises).
Why It Works (Competitive Advantages)
- ✔Proprietary bacteriophage platform and manufacturing capabilities
- ✔Positive regulatory designations (QIDP, EOP2 alignment for AP-SA02)
- ✔Addresses critical unmet need for antibiotic-resistant infections
Economic Moat: Narrow (Intangible Assets/IP (proprietary phage library and formulation), Regulatory Barriers (QIDP designation offers exclusivity incentives))
What Our Analysis Says
DVR Score as of April 26, 2026
Armata Pharmaceuticals (ARMP) maintains its highly speculative, high-risk, high-reward profile. The company's innovative phage therapy for antibiotic-resistant infections addresses a critical unmet medical need, validated by strong regulatory progress including FDA End-of-Phase 2 alignment for AP-SA02 and QIDP designation. This positions ARMP for potential market leadership and significant 10x growth if successful. However, the Q4 2025 financials, including a substantial EPS miss and critically low cash position (from previous analysis, derived from 10-K filed March 25, 2026), coupled with an auditor's 'going concern' warning, highlight severe immediate financial risk and a high likelihood of significant future dilution. While clinical momentum is robust and analyst sentiment is positive, the capital constraints introduce considerable short-term volatility and execution risk, balancing the impressive pipeline progress.